(Q37803118)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975737%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

title

Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975737%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975737%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

D H Roukos

series ordinal

1

1 reference

23 August 2017

language of work or name

1 reference

26 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975737%20AND%20SRC:MED&resulttype=core&format=json

The Pharmacogenomics Journal

14 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975737%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975737%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

81-92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975737%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975737%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/tpj.2010.81

14 January 2020

exact match

0 references

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

The genomic landscapes of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Sensitive digital quantification of DNA methylation in clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

A small-cell lung cancer genome with complex signatures of tobacco exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

A comprehensive catalogue of somatic mutations from a human cancer genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Genome remodelling in a basal-like breast cancer metastasis and xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Complex landscapes of somatic rearrangement in human breast cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Modelling the molecular circuitry of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Microenvironmental regulation of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Molecular networks as sensors and drivers of common human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Reverse engineering the genotype-phenotype map with natural genetic variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Timeline: Chemotherapy and the war on cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Identification of the breast cancer susceptibility gene BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

E-cadherin germline mutations in familial gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

BRCA1 and BRCA2: 1994 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Genome-wide association studies: how predictable is a person’s cancer risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

The distinctive nature of HER2-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Quo vadis with targeted drugs in the 21st century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

New, but not improved? Incorporating comparative-effectiveness information into FDA labeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Systems biology: When it is time to die.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Cancer: The nuances of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Micrometastases or isolated tumor cells and the outcome of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

HER2 signatures in breast cancer: ready to go to print?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Next-generation DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

The landscape of somatic copy-number alteration across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Heteroplasmic mitochondrial DNA mutations in normal and tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Risk factors for the incidence of breast cancer: do they affect survival from the disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Performance of common genetic variants in breast-cancer risk models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

On the nature of susceptibility to cancer. The presidential address

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Oncogenic transformation and experimental models of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Genetic progression and the waiting time to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

From tumor size and HER2 status to systems oncology for very early breast cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Chemical biology: A Notch above other inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Has the revolution arrived?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Multiple personal genomes await

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

21 January 2018

Point: Hypotheses first.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

21 January 2018

Counterpoint: Data first

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Human genome at ten: The human race.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Human genome at ten: Life is complicated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Parliament needs members who are scientifically literate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

21 January 2018

The human genome at ten

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

Human genome at ten: The sequence explosion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.81

21 January 2018

Identifiers

DOI

10.1038/TPJ.2010.81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975737%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference